

DT 07-DEC-1998 (first entry)

61 YCBETCCCAACSTPDCSTIYEBDAEKEOKVI IOSVSGTCTERTIAOCCEOEFEVYDCSHDEDA 120

Db 61 lreelggaagstpsgilyeapkeqkvlqsvctytdtlaqceevydcsheda 120
 QY 121 GASTENPESSEFPGVPLADGPHCKGKGPVEVHONWYVCTGWSLRAAKVVCROLG 180
 Db 121 gasteenpessfpgvpladgphckgkpgvevhnwytvctgwsllraakvvcrolg 180
 QY 181 GQAVLTGPKRNEYAPFPILWSUMSSPFEATLQDCPSGPKWKNTHNHEETWVEED 240
 Db 181 gqavltgpkrneayapfpilwsumsspfeatlqdcpsgpkwnthnheetwveed 240
 QY 241 PFDELVVGSDNLCSKRLVHLKQWSSVLELWNEKEKELVVCWKEGCKSLSPSPDRKC 300
 Db 241 pfdelvvgdnlcskrlvhlkqwsdvcdnwgekdgwvckqkgckslspsfdrkc 300
 QY 301 YGPGVGRIMLNVKCSSEFQSLFKAQHREWFPHDCTHQEDVAVICS 346
 Db 301 ypgvgrimlwnvrcsgeeqslsqchrfwghdthqgdvavics 346

RESULT 4
 AAW64537
 ID AAW64537 standard; Protein: 347 AA.

XX AC AAW64537;
 XX DT 21-OCT-1998 (first entry)
 XX DE Human liver cell clone HP01148 protein.
 XX KW Transmembrane domain; human; nutrition; cytokine; cell proliferation;
 XX KW differentiation; immune system; stimulator; suppressor; regulator;
 XX KW hematopoiesis; activin; inhibitor; chemotactic; chemokine; receptor;
 XX KW haemostatic; thrombolytic; ligand; anti-inflammatory; tumour.
 XX OS Homo sapiens.
 XX PN WO9821328-A2.
 XX PD 22-MAY-1998.
 XX PF 07-NOV-1997; 97WO-JP04056.
 XX PR 13-NOV-1996; 96JP-0301429.
 XX PP (PPT-) PROTEKENE INC
 XX (SAGA) SAGAMI CHEM RES CENTRE.

Kato S, Kobayashi M, Sekine S, Yamaguchi T;

WPI: 1998-297932/46.
 N-PSDB: AAV49556, AAV49557.
 Human protein having transmembrane domain - useful for, e.g.
 research and nutrition

Claim 1: Page 95-96; 205pp; English.

AAW64534-W64558 represent human proteins containing a transmembrane
 domain. These proteins can be used for, e.g. research and nutrition, and
 may have cytokine and cell proliferation/differentiation, immune
 stimulating/suppressing, haematopoiesis regulating, tissue growth,
 activin/inhibin, chemotactic/chemokinetic, haemostatic and thrombolytic,
 receptor/ligand, anti-inflammatory or tumour inhibiting activity

sequence 347 AA;

seq: 151
 local 151
 match 151
 Local Similarity 94.8%; Score 1939; DB 19; Length 347;
 Res 345; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1 MALLFSLILAICTRPFGLASPSGVLVGGLRPCPGVPEKQKQWCTVCDPWTKRVAV 60

Aug 21

Db 1 mallfslilaicttrpfglaspsgvlvvgllhrcegrveeqkgqgtvcdgwdikdvav 60
 QY 61 LQRELGGGAASGTPSGILYEPPEAKKQVLLQSVSCTGTEDTLAOCQEEVYDCSHEDA 120
 Db 61 lqrelgggaastpsgilyeppeakkeqkvlqsvsctgtedtlacqeevydcsheda 120
 QY 121 GASCENPESSEFPGVPLADGPHCKGKGPVEVHONWYVCTGWSLRAAKVVCROLG 180
 Db 121 gascenpessfpgvpladgphckgkpgvevhnwytvctgwsllraakvvcrolg 180
 QY 181 GQAVLTGPKRNEYAPFPILWSUMSSPFEATLQDCPSGPKWKNTHNHEETWVEED 240
 Db 181 gqavltgpkrneayapfpilwsumsspfeatlqdcpsgpkwnthnheetwveed 240
 QY 241 PFDELVVGSDNLCSKRLVHLKQWSSVLELWNEKEKELVVCWKEGCKSLSPSPDRKC 300
 Db 241 pfdelvvgdnlcskrlvhlkqwsdvcdnwgekdgwvckqkgckslspsfdrkc 300
 QY 301 YGPGVGRIMLNVKCSSEFQSLFKAQHREWFPHDCTHQEDVAVICS 346
 Db 301 ypgvgrimlwnvrcsgeeqslsqchrfwghdthqgdvavics 346

RESULT 5

AAW64591
 ID AAW64591 standard; Protein: 1785 AA.

XX AC AAW64591;
 XX DT 23-OCT-1998 (first entry)
 XX DE Human SRCP protein.
 XX KW Scavenger receptor cysteine rich domain; SRCP; diagnosis; treatment;
 XX KW nervous system; medullo-blastoma; glioma; breast; detection;
 XX KW autoantibody; ss.
 XX OS Homo sapiens.
 XX PN WO9830687-A2.
 XX PD 16-JUL-1998.
 XX PF 09-JAN-1998; 98WO-DE00056.
 XX PR 18-JUL-1997; 97DK-1030997.
 XX PR 09-JAN-1997; 97DE-1000519.
 XX PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX PI Mollenhauer J, Pousta A;
 XX DR WPI: 1998-399136/34.
 XX DR N-PSDB: AAV49652.
 XX PT Proteins containing scavenger receptor, cysteine rich domain -
 XX useful for diagnosis and treatment of tumours
 XX Claim 2: Fig 2; 54pp; German.

This sequence represents a human protein which contains a SRCP (scavenger
 receptor, cysteine-rich) domain. The gene and encoded protein can be used
 to diagnose or treat tumours, particularly of the nervous system
 (medullo-blastoma or glioma) or breast. The DNA sequence and probes
 derived from it, are used to identify genes that express SRCP-domain
 containing proteins, to determine the form in which these proteins exist
 and to assess the significance of individual forms on cellular
 properties. The protein can be used to detect the presence of
 autoantibodies and antibodies which regulate its expression.

Sequence 1785 AA;

Jiang, D.
09/19/04 462
seg. 10 148

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.
tein - protein search, using sw model
August 20, 2002, 12:57:10 ; Search time 32.8 seconds
(without alignments)
1175.079 Million cell updates/sec

US-09-904-462a-148
Kt score: 1947
Ince: 1 MALLFSLLILAICTRPGFLAS.....RFWGFHCTHCEVAVICSV 347

ing table: BLOSUM62
Gapop 10.0 , Gapext 0.5

ched: 747574 seqs, 111073796 residues

al number of hits satisfying chosen parameters: 747574

imum DB seq length: 0

imum nr seq length: 2000000000

ft-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_032802.*

- 1: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
- 2: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
- 3: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
- 4: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
- 5: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
- 6: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
- 7: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
- 8: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
- 9: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
- 10: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
- 11: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
- 12: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
- 13: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
- 14: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
- 15: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
- 16: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
- 17: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
- 18: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
- 19: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
- 20: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
- 21: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
- 22: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1947	100.0	347	20	AAV13369
2	1947	100.0	347	22	AAH80237
3	1943	99.8	347	19	AAW68200
4	1939	99.6	347	19	AAW64537
5	721	37.0	1785	19	AAW64591
6	719	36.9	422	22	AAE09446
7	695	35.7	552	22	AAE09447
8	691.5	35.5	1453	22	AAE66037
9	690	35.4	1319	22	AAE66040
10	690	35.4	1413	22	AAE66039
11	686	35.2	1121	22	AAH39493

12	686	35.2	1124	22	AAH41279
13	686	35.2	1124	22	AAH41280
14	686	35.2	1124	22	AAH39494
15	680	34.9	1120	22	AAU00396
16	669	34.4	821	22	AAU27709
17	663	34.1	1436	22	AAH60088
18	643	33.0	822	20	AAW99087
19	643	33.0	875	20	AAW83361
20	632	32.5	761	20	AAW99088
21	632	32.5	761	20	AAW83362
22	582.5	29.9	1290	18	AAW07609
23	532.5	27.3	608	22	AAE11936
24	514	26.4	147	22	ABH12145
25	480	24.7	753	21	ABH00073
26	480	24.7	753	21	ABH00073
27	478.5	24.6	573	21	AAH49534
28	475	24.4	666	19	AAW64590
29	473	24.3	641	21	AAH12307
30	472	24.2	732	22	AAE11927
31	472	24.2	732	22	AAE11935
32	470.5	24.2	769	22	AAE11940
33	463.5	23.8	754	21	AAH00078
34	453.5	23.3	774	21	AAH00077
35	452	23.2	757	21	AAH19127
36	446.5	22.9	1186	22	ABH60092
37	435	22.3	408	21	AAH51785
38	435	22.3	443	21	AAH72125
39	435	22.3	443	21	AAH49549
40	426.5	21.9	392	21	AAH51784
41	406.5	20.9	186	22	AAH25385
42	345.5	17.7	225	22	AAH25317
43	319	16.4	180	21	AAH54244
44	315.5	16.2	136	22	AAH73568
45	305.5	15.7	511	22	ABH60018

ALIGNMENTS

RESULT	1
AAV13369	AAV13369 standard; Protein: 347 AA.
TO	AAV13369
AC	AAV13369,
XX	25-JUN-1999 (first entry)
DT	Amino acid sequence of protein P40229.
XX	Secreted protein; transmembrane protein; human; enterocolitis; collagenar-Ellison syndrome; gastrointestinal ulceration; congenital microvillus atrophy; skin disease; cell growth; abnormal keratinocyte differentiation; psoriasis; epithelial cancer; Parkinson's disease; Alzheimer's disease; ALS; neuropathy; fibromodulin; dermal scarring; Usher Syndrome; Atrophla areata; anti-thrombotic; wound healing; tissue repair.
DE	Homo sapiens.
XX	OS
XX	XX
PN	WC0914328-A2.
PD	25-MAR-1999.
XX	16-SEP-1998; 98WO-US19330.
XX	25-NOV-1997; 97US-0066840
PR	17-SEP-1997; 97US-0059113.
PR	17-SEP-1997; 97US-0059115.
PR	17-SEP-1997; 97US-0059117.
PR	17-SEP-1997; 97US-0059119.
PR	17-SEP-1997; 97US-0059121.
PR	17-SEP-1997; 97US-0059122.
PR	17-SEP-1997; 97US-0059184.

PR 18-SEP-1997; 97US-0059263.
 PR 18-SEP-1997; 97US-0059266.
 PR 15-OCT-1997; 97US-0062125.
 PR 17-OCT-1997; 97US-0062385.
 PR 17-OCT-1997; 97US-0062387.
 PR 21-OCT-1997; 97US-0063485.
 PR 24-OCT-1997; 97US-0062814.
 PR 24-OCT-1997; 97US-0063415.
 PR 24-OCT-1997; 97US-0063045.
 PR 24-OCT-1997; 97US-0063120.
 PR 24-OCT-1997; 97US-0063121.
 PR 24-OCT-1997; 97US-0063127.
 PR 24-OCT-1997; 97US-0063128.
 PR 27-OCT-1997; 97US-0063324.
 PR 27-OCT-1997; 97US-0063327.
 PR 28-OCT-1997; 97US-0063547.
 PR 28-OCT-1997; 97US-0063542.
 PR 28-OCT-1997; 97US-0063544.
 PR 28-OCT-1997; 97US-0063549.
 PR 28-OCT-1997; 97US-0063550.
 PR 28-OCT-1997; 97US-0063564.
 PR 29-OCT-1997; 97US-0063435.
 PR 29-OCT-1997; 97US-0063704.
 PR 29-OCT-1997; 97US-0063732.
 PR 29-OCT-1997; 97US-0063738.
 PR 29-OCT-1997; 97US-0063744.
 PR 29-OCT-1997; 97US-0064215.
 PR 31-OCT-1997; 97US-0063745.
 PR 31-OCT-1997; 97US-0063870.
 PR 31-OCT-1997; 97US-0064103.
 PR 31-OCT-1997; 97US-0064248.
 PR 07-NOV-1997; 97US-0064404.
 PR 12-NOV-1997; 97US-0065185.
 PR 17-NOV-1997; 97US-0065846.
 PR 18-NOV-1997; 97US-0065693.
 PR 21-NOV-1997; 97US-0065129.
 PR 21-NOV-1997; 97US-0066364.
 PR 24-NOV-1997; 97US-0066772.
 PR 24-NOV-1997; 97US-0066466.
 PR 24-NOV-1997; 97US-0065770.
 PR 24-NOV-1997; 97US-0066511.
 PR 24-NOV-1997; 97US-0066453.
 (GENTECH INC.)

Chen J, Goddard A, Gurney AL, Pennica D, Wood WI, Yuan J;

WPI: 1999-229533/13.

N-PSDP: AAX52240.

New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration

Claim 12: Fig 54: 320pp: English.

AA13344-403 represent secreted and transmembrane human proteins. The cDNA sequences are obtained from cDNA libraries, prepared from fetal lung, fetal kidney, fetal brain, liver and fetal retina. The encoded polypeptides have specific uses based on their homology to known polypeptides, e.g. Pp261 and Pp262 can be used for disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions. A human polypeptide, Pp261, is a target for anti-tumor drugs. Pp262 can be used as a target for anti-tumor drugs. Pp263 may be used in the treatment of ulcer syndrome or atrophic gastritis. Pp264 can be used as a thrombotic agent. Pp265 polypeptides and portions may have

CC therapeutic applications in wound healing and tissue repair; Pp317 can be used for treating problems of the kidney, uterus, endometrium, blood vessels, or related tissue, e.g. in the heart of genital tract.

XX Sequence 347 AA;

Query Match 100.0%, Score 1947, DB 20, Length 347;
 Best Local Similarity 100.0%, Pred No. 14e-153;
 Matches 347; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALLFSLILALCTIPPTAFSPQVPLVQGRHPCBPVEVECFKQWSTVCHDGMIDKDVAV 60
 DQ 1 mallfslilalactipptafspqvpvlvqgrhpcbpvevecfkqwtvchdgmidkdvav 60
 QY 61 LCRRLQGMASNSHLSGIIYEPFAEFKQKVLIOVSCTGTTLTLCQCEVEYDCSHDEDA 120
 DQ 61 lcrqlqgmanshlsghiiyepfaefkqkvliovsctgttlttlcqcveeydcshdeda 120
 QY 121 GASCNPFSSPTVTEGVFLADPGCHCKGRVVEVKHQWKTTCOTGWSLPAKVYCRQLG 180
 DQ 121 gascnpfssptvtegvfladpgchckgrvvevkhqwkttcotgwsllpaakvycrqlg 180
 QY 181 GSPAVLILKFAFNKAYTFFPIWLSQMSQSPREATLQCPSPGKNTCNHDEDTWVECD 240
 DQ 181 gspavlllkfayfnkaytffpiwlsqmscsreatlqcpspgkntcnhdedtwveced 240
 QY 241 PFDLPLVSGINDSSPLVLELHKGVWSSVQDENWKEKEDQVVCQKLSLSPSEPRPKC 300
 DQ 241 pfdlplvsgindssplvlelkhgkvwssvqdenwkekedqvvccklsgslspsfdrkc 300
 QY 301 YGPGVPTWITINVPSCGSEFQSLPQCHPFGFHDCTHOEDVAVTCV 347
 DQ 301 ypgvptwitinvpscgsfqlpqcchpfgfhcthoedvavtcv 347

RESULT 2

AA080237 AAB80237 standard; Protein: 347 AA.

XX AC AAB80237;

XX XX 24-APR-2001 (first entry)

XX DE Human PRO229 protein.

XX KW Human; PFC; dermatological, antipsoriatic, cytostatic; antiinflammatory;
 KW antiparkinsonian neurotropic, neuroprotective; vulvectomy, cardiac,
 KW antiangiogenic; vasodilator; antiasthmatic; antirheumatic; cancer;
 KW antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;
 KW ophthalmological; gene therapy, skin disease, gastrointestinal disorder,
 XX ischaemia; inflammation.

XX OS Homo sapiens.

XX FN WO200104311-A1.

XX PD 18-JAN-2001.

XX XX 24-APR-2001 (first entry)

XX PK 07-JUL-1999; 99US-0143048.

XX PF 26-MAR-1999; 99US-0145698.

XX PF 24-MAR-1999; 99US-0145698.

XX PF 08-SEP-1999; 99US-020594.

XX PF 13-SEP-1999; 99US-020944.

XX PF 15-SEP-1999; 99US-021099.

XX PF 15-SEP-1999; 99US-021547.

XX PF 05-OCT-1999; 99US-024089.

XX PF 29-NOV-1999; 99US-028214.

PR 18-SEP-1997; 97US-0059263.
 PR 18-SEP-1997; 97US-0059266.
 PR 15-OCT-1997; 97US-0062125.
 PR 17-OCT-1997; 97US-0062385.
 PR 17-OCT-1997; 97US-0062387.
 PR 21-OCT-1997; 97US-0063485.
 PR 24-OCT-1997; 97US-0062814.
 PR 24-OCT-1997; 97US-0063415.
 PR 24-OCT-1997; 97US-0063045.
 PR 24-OCT-1997; 97US-0063120.
 PR 24-OCT-1997; 97US-0063121.
 PR 24-OCT-1997; 97US-0063127.
 PR 24-OCT-1997; 97US-0063128.
 PR 27-OCT-1997; 97US-0063324.
 PR 27-OCT-1997; 97US-0063327.
 PR 28-OCT-1997; 97US-0063547.
 PR 28-OCT-1997; 97US-0063542.
 PR 28-OCT-1997; 97US-0063544.
 PR 28-OCT-1997; 97US-0063549.
 PR 28-OCT-1997; 97US-0063550.
 PR 28-OCT-1997; 97US-0063564.
 PR 29-OCT-1997; 97US-0063435.
 PR 29-OCT-1997; 97US-0063704.
 PR 29-OCT-1997; 97US-0063732.
 PR 29-OCT-1997; 97US-0063738.
 PR 29-OCT-1997; 97US-0063744.
 PR 29-OCT-1997; 97US-0064215.
 PR 31-OCT-1997; 97US-0063745.
 PR 31-OCT-1997; 97US-0063870.
 PR 31-OCT-1997; 97US-0064103.
 PR 31-OCT-1997; 97US-0064248.
 PR 07-NOV-1997; 97US-0064404.
 PR 12-NOV-1997; 97US-0065185.
 PR 17-NOV-1997; 97US-0065846.
 PR 18-NOV-1997; 97US-0065693.
 PR 21-NOV-1997; 97US-0065129.
 PR 21-NOV-1997; 97US-0066364.
 PR 24-NOV-1997; 97US-0066772.
 PR 24-NOV-1997; 97US-0066466.
 PR 24-NOV-1997; 97US-0065770.
 PR 24-NOV-1997; 97US-0066511.
 PR 24-NOV-1997; 97US-0066453.
 (GENTECH INC.)

Chen J, Goddard A, Gurney AL, Pennica D, Wood WI, Yuan J;

WPI: 1999-229533/13.

N-PSDP: AAX52240.

New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration

Claim 12: Fig 54: 320pp: English.

AA13344-403 represent secreted and transmembrane human proteins. The cDNA sequences are obtained from cDNA libraries, prepared from fetal lung, fetal kidney, fetal brain, liver and fetal retina. The encoded polypeptides have specific uses based on their homology to known polypeptides, e.g. Pp261 and Pp262 can be used for disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions. A human polypeptide, Pp261, is a target for anti-tumor drugs. Pp262 can be used as a target for anti-tumor drugs. Pp263 may be used in the treatment of ulcer syndrome or atrophic gastritis. Pp264 can be used as a thrombotic agent. Pp265 polypeptides and portions may have

PR 18-SEP-1997; 97US-0059263.
 PR 18-SEP-1997; 97US-0059266.
 PR 15-OCT-1997; 97US-0062125.
 PR 17-OCT-1997; 97US-0062385.
 PR 17-OCT-1997; 97US-0062387.
 PR 21-OCT-1997; 97US-0063485.
 PR 24-OCT-1997; 97US-0062814.
 PR 24-OCT-1997; 97US-0063415.
 PR 24-OCT-1997; 97US-0063045.
 PR 24-OCT-1997; 97US-0063120.
 PR 24-OCT-1997; 97US-0063121.
 PR 24-OCT-1997; 97US-0063127.
 PR 24-OCT-1997; 97US-0063128.
 PR 27-OCT-1997; 97US-0063324.
 PR 27-OCT-1997; 97US-0063327.
 PR 28-OCT-1997; 97US-0063547.
 PR 28-OCT-1997; 97US-0063542.
 PR 28-OCT-1997; 97US-0063544.
 PR 28-OCT-1997; 97US-0063549.
 PR 28-OCT-1997; 97US-0063550.
 PR 28-OCT-1997; 97US-0063564.
 PR 29-OCT-1997; 97US-0063435.
 PR 29-OCT-1997; 97US-0063704.
 PR 29-OCT-1997; 97US-0063732.
 PR 29-OCT-1997; 97US-0063738.
 PR 29-OCT-1997; 97US-0063744.
 PR 29-OCT-1997; 97US-0064215.
 PR 31-OCT-1997; 97US-0063745.
 PR 31-OCT-1997; 97US-0063870.
 PR 31-OCT-1997; 97US-0064103.
 PR 31-OCT-1997; 97US-0064248.
 PR 07-NOV-1997; 97US-0064404.
 PR 12-NOV-1997; 97US-0065185.
 PR 17-NOV-1997; 97US-0065846.
 PR 18-NOV-1997; 97US-0065693.
 PR 21-NOV-1997; 97US-0065129.
 PR 21-NOV-1997; 97US-0066364.
 PR 24-NOV-1997; 97US-0066772.
 PR 24-NOV-1997; 97US-0066466.
 PR 24-NOV-1997; 97US-0065770.
 PR 24-NOV-1997; 97US-0066511.
 PR 24-NOV-1997; 97US-0066453.
 (GENTECH INC.)

Chen J, Goddard A, Gurney AL, Pennica D, Wood WI, Yuan J;

WPI: 1999-229533/13.

N-PSDP: AAX52240.

New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration

Claim 12: Fig 54: 320pp: English.

AA13344-403 represent secreted and transmembrane human proteins. The cDNA sequences are obtained from cDNA libraries, prepared from fetal lung, fetal kidney, fetal brain, liver and fetal retina. The encoded polypeptides have specific uses based on their homology to known polypeptides, e.g. Pp261 and Pp262 can be used for disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions. A human polypeptide, Pp261, is a target for anti-tumor drugs. Pp262 can be used as a target for anti-tumor drugs. Pp263 may be used in the treatment of ulcer syndrome or atrophic gastritis. Pp264 can be used as a thrombotic agent. Pp265 polypeptides and portions may have

Aug 21 11

GenCore version 4.5
Copyright (c) 1993 - 2000 Computer Ltd.

protein search, using sw model

August 20, 2002, 12:57:45, Search time 13.07 seconds
(without alignments)
648,454 Million cell updates/sec

US-09-904-462A-148

Score: 1947

Sequence: 1 MALLFSLLILACTRPGPLAS RFWGPHDCTHQRDVAIVSV 347

Gaping table: BLOSUM62

Gaping table: Gapop 10.0, Gapext 0.5

Matched: 231628 seqs, 24425594 residues

Number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

Issued Patents_AA*

- 1: /cgn2.6/ptodata/2/1aa/5A_COMB.pep.*
- 2: /cgn2.6/ptodata/2/1aa/5B_COMB.pep.*
- 3: /cgn2.6/ptodata/2/1aa/6A_COMB.pep.*
- 4: /cgn2.6/ptodata/2/1aa/6B_COMB.pep.*
- 5: /cgn2.6/ptodata/2/1aa/6C_COMB.pep.*
- 6: /cgn2.6/ptodata/2/1aa/6D_COMB.pep.*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	Hit	Description
1	1938	99.5	346	3	US-09-034-916-2	Sequence 2, Appl
2	721	37.0	1785	4	US-09-341-587-3	Sequence 3, Appl
3	588	30.2	101	3	US-09-034-916-4	Sequence 4, Appl
4	586	30.1	102	3	US-09-034-916-5	Sequence 5, Appl
5	582.5	29.9	1290	1	US-08-470-350B-2	Sequence 2, Appl
6	553	28.4	101	3	US-09-034-916-3	Sequence 3, Appl
7	480	24.7	753	4	US-09-276-400-2	Sequence 2, Appl
8	480	24.7	753	4	US-09-448-076-2	Sequence 2, Appl
9	475	24.4	666	4	US-09-341-587-1	Sequence 2, Appl
10	463.5	23.8	754	4	US-09-276-400-8	Sequence 1, Appl
11	463.5	23.8	754	4	US-09-448-076-8	Sequence 8, Appl
12	453.5	23.3	774	4	US-09-276-400-7	Sequence 7, Appl
13	453.5	23.3	774	4	US-09-448-076-7	Sequence 7, Appl
14	285	14.6	100	3	US-09-034-916-15	Sequence 15, Appl
15	282	14.5	100	3	US-09-034-916-17	Sequence 17, Appl
16	279	14.3	100	3	US-09-034-916-10	Sequence 10, Appl
17	266	13.7	100	3	US-09-034-916-11	Sequence 11, Appl
18	260.5	13.4	495	2	US-08-794-795-2	Sequence 2, Appl
19	260.5	13.4	495	4	US-09-249-220-2	Sequence 2, Appl
20	260.5	13.4	520	2	US-08-794-795-6	Sequence 6, Appl
21	260.5	13.4	520	4	US-09-249-200-6	Sequence 6, Appl
22	258.5	13.3	451	1	US-08-154-365-2	Sequence 2, Appl
23	254.5	13.1	101	3	US-09-034-916-9	Sequence 9, Appl
24	252.5	13.0	451	1	US-08-453-117-2	Sequence 2, Appl
25	252.5	13.0	451	2	US-08-948-222-2	Sequence 2, Appl
26	252.5	13.0	451	2	US-08-973-145-2	Sequence 2, Appl
27	252.5	13.0	451	4	US-09-276-400-10	Sequence 10, Appl

28	252.5	13.0	451	4	US-09-448-076-10	Sequence 10, Appl
29	252.5	13.0	451	5	US-09-448-076-11	Sequence 2, Appl
30	251	12.9	101	4	US-09-518-046-15	Sequence 15, Appl
31	247.5	12.7	489	2	US-08-794-795-7	Sequence 7, Appl
32	247.5	12.7	489	4	US-09-249-200-7	Sequence 7, Appl
33	247.5	12.7	518	1	US-08-392-367B-2	Sequence 2, Appl
34	247.5	12.7	518	3	US-08-893-467A-2	Sequence 2, Appl
35	247	12.7	101	4	US-09-518-046-16	Sequence 16, Appl
36	246	12.6	453	6	US-09-034-916-7	Sequence 7, Appl
37	229.5	11.8	95	3	US-09-034-916-7	Sequence 7, Appl
38	216	11.1	585	1	US-08-477-674-10	Sequence 10, Appl
39	216	11.1	585	1	US-08-477-674-10	Sequence 10, Appl
40	216	11.1	585	2	US-08-316-714-10	Sequence 10, Appl
41	216	11.1	585	3	US-08-473-673-10	Sequence 10, Appl
42	207	10.6	100	4	US-09-034-916-13	Sequence 13, Appl
43	205.5	10.6	100	3	US-09-034-916-12	Sequence 12, Appl
44	193.5	9.9	349	3	US-08-630-172-6	Sequence 6, Appl
45	193.5	9.9	349	4	US-09-375-419-6	Sequence 6, Appl

ALIGNMENTS

RESULT 1
US-09-034-916-2
Sequence 2, Application US/09034916
Patent No. 6046314

GENERAL INFORMATION:
APPLICANT: GEBE, JOHN A.

APPLICANT: SIADAK, ANTHONY W.

APPLICANT: ALEJANDRO A.

TITLE OF INVENTION: SPALPHA, A NOVEL SCAVENGER RECEPTOR

TITLE OF INVENTION: CYSTEINE-RICH DOMAIN-CONTAINING POLYPEPTIDE AND MONOCLONAL

TITLE OF INVENTION: ANTIBODIES THEREOF

NUMBER OF SEQUENCES: 17

CORRESPONDENCE ADDRESS:

ADDRESSEE: ROBINS & ASSOCIATES

STREET: 90 MIDDLEFIELD ROAD, SUITE 200

CITY: MENLO PARK

STATE: CALIFORNIA

COUNTRY: USA

ZIP: 94025

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1 0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/034,916

FILING DATE: 04-MAR-1998

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/039,956

FILING DATE: 06-MAR-1997

ATTORNEY/AGENT INFORMATION:

NAME: ROBINS, ROBERTA L.

REGISTRATION NUMBER: 33,208

REFERENCE/INVENT NUMBER: 5,908,002

TELEPHONE: (650) 325-7812

TELEFAX: (650) 325-7823

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 345 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-09-034-916-2

Query Match: 99.5%, Score 1938, DB 3, Length 345;
Best Local Similarity: 100%, Prol No. 2 7e-177;
Matches 445, Conservative 0, Mismatches 0; Indels 0; Gaps 0;

